Home LiteratureArticle Details
PMID: 7712595 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review

Eicosanoids and the immunology of cancer.

Cancer metastasis reviews ·Vol. 13 ·No. 3-4 ·1994-12-00 ·Pages 337-48

Young MR

Abstract

Studies in both cancer patients and in animal tumor models have shown that immune defenses can mediate destruction of tumor, but these defenses are often functioning at a suppressed or suboptimal level. Frequently, prostaglandins, mainly PGE2, have been implicated in this tumor-associated subversion of immune function, with immune reactivities to tumor typically being enhanced by prostaglandin synthesis inhibitor. Both the tumor and tumor-induced host immune suppressive macrophages have the capacity to suppress immune functions through their production of PGE2. Although the inhibitory functions have been more widely studied, recent evaluations of the effects of PGE2 have led to the surprising realization that not all of the PGE2's effects are inhibitory to immune function. Summarized below are some of the well characterized inhibitory effects of PGE2, as well as the lesser studied stimulatory effects of PGE2 toward the effector cells that are considered to be important in the immune defense against cancer.

MeSH Terms
Animals Dinoprostone/biosynthesis,immunology Eicosanoids/immunology Humans Immunity, Cellular/immunology Macrophages/immunology,metabolism Neoplasms/immunology,metabolism Neoplasms, Experimental/immunology,metabolism
Chemicals
Eicosanoids Dinoprostone
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Young M R
Research Service, Department of Veterans Affairs, Hines VA Hospital, IL, USA.
References (86)
86 references, click to expand
  1. Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis.
    Res Immunol. 1992 Feb;143(2):199-204 PMID: 1574648
  2. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).
    J Immunol. 1991 Aug 1;147(3):874-82 PMID: 1713608
  3. The LMI test in colon, breast and lung cancer long survivors.
    Panminerva Med. 1992 Apr-Jun;34(2):60-4 PMID: 1408329
  4. Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer.
    Cancer. 1991 Sep 15;68(6):1279-84 PMID: 1873782
  5. Protein phosphatases limit tumor motility.
    Int J Cancer. 1993 Jul 30;54(6):1036-41 PMID: 8392979
  6. Altered eicosanoid levels in human colon cancer.
    J Lab Clin Med. 1993 Nov;122(5):518-23 PMID: 8228569
  7. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2.
    Cancer Res. 1988 Dec 1;48(23):6826-31 PMID: 2972359
  8. Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma.
    J Natl Cancer Inst. 1986 Aug;77(2):425-9 PMID: 2942724
  9. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Cancer Res. 1991 Aug 15;51(16):4199-205 PMID: 1868441
  10. T-cell subsets and cytokines in parasitic infections.
    Immunol Today. 1992 Nov;13(11):445-8 PMID: 1476599
  11. In vitro and in vivo activated T cells display increased sensitivity to PGE2.
    Cell Immunol. 1991 Dec;138(2):289-99 PMID: 1657408
  12. A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Basis, clinical toxicity, and immunomodulatory effects.
    Biotherapy. 1991;3(3):245-51 PMID: 1854593
  13. Effect of LTB4 on the inhibition of natural cytotoxic activity by PGE2.
    Cell Immunol. 1992 Jan;139(1):248-58 PMID: 1309490
  14. Tumour dormancy: initiation, maintenance and termination in animals and humans.
    Can J Surg. 1991 Aug;34(4):321-5 PMID: 1868387
  15. Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses.
    Otolaryngol Head Neck Surg. 1992 Feb;106(2):149-58 PMID: 1738546
  16. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.
    Cancer Immunol Immunother. 1993;36(3):141-8 PMID: 8439974
  17. Cytokines and suppressor macrophages cause tumor-bearing host CD8+ T cells to suppress recognition of allogeneic and syngeneic MHC class II molecules.
    J Leukoc Biol. 1992 Dec;52(6):661-9 PMID: 1464737
  18. Tumor dormancy and the effect of selected drugs on the tumor-dormant state.
    Lab Anim Sci. 1992 Dec;42(6):555-60 PMID: 1479806
  19. Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer.
    Cancer Immunol Immunother. 1993 Jul;37(2):119-24 PMID: 8391391
  20. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Cancer Res. 1992 Mar 1;52(5):1129-36 PMID: 1531321
  21. Bronchogenic carcinoma: immunologic aspects.
    Mayo Clin Proc. 1993 Apr;68(4):386-92 PMID: 8455400
  22. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.
    Cancer Immunol Immunother. 1992;35(1):14-8 PMID: 1535284
  23. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Cancer Res. 1993 Dec 1;53(23):5654-62 PMID: 8242620
  24. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.
    Cancer Immunol Immunother. 1991;33(5):319-26 PMID: 1651160
  25. Activation of protein kinase A increases the in vitro invasion, migration, and adherence to reconstituted basement membrane by Lewis lung carcinoma tumor cells.
    Invasion Metastasis. 1992;12(5-6):253-63 PMID: 1298738
  26. Update on immunology of head and neck cancer.
    Med Clin North Am. 1993 May;77(3):625-31 PMID: 8492614
  27. Promotion of metastases by tumor necrosis factor in rats bearing Dunning R3327 MAT-LyLu prostatic cancer.
    Urol Int. 1993;51(2):85-8 PMID: 8351760
  28. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia.
    Cancer Res. 1991 Feb 1;51(3):880-5 PMID: 1988128
  29. Effect of prostaglandin E2 (PGE2) on IL-3/granulocyte-macrophage colony-stimulating factor production by T helper cells. Mode of stimulation and presence of costimulation can determine response to PGE2.
    J Immunol. 1993 Mar 1;150(5):1680-90 PMID: 8436811
  30. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2.
    Clin Exp Metastasis. 1992 Jul;10(4):239-52 PMID: 1617832
  31. Regulation of human cytolytic lymphocyte responses by interleukin-12.
    Cell Immunol. 1992 Aug;143(1):127-42 PMID: 1352483
  32. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma.
    J Natl Cancer Inst. 1986 Apr;76(4):745-50 PMID: 3457207
  33. In vitro effect of indomethacin on mitogen-induced lymphoproliferative response in lung cancer patients.
    Neoplasma. 1992;39(2):129-32 PMID: 1326720
  34. Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis factor alpha.
    Cancer Res. 1992 Jul 15;52(14):3880-5 PMID: 1617664
  35. Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck.
    Arch Otolaryngol Head Neck Surg. 1992 May;118(5):526-8 PMID: 1571128
  36. Association of a functional prostaglandin E2-protein kinase A coupling with responsiveness of metastatic Lewis lung carcinoma variants to prostaglandin E2 and to prostaglandin E2-producing nonmetastatic Lewis lung carcinoma variants.
    Cancer Res. 1990 May 15;50(10):2973-8 PMID: 2159367
  37. Effects of fish oil and corn oil diets on prostaglandin-dependent and myelopoiesis-associated immune suppressor mechanisms of mice bearing metastatic Lewis lung carcinoma tumors.
    Cancer Res. 1989 Apr 15;49(8):1931-6 PMID: 2522813
  38. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo.
    J Natl Cancer Inst. 1984 Apr;72(4):919-22 PMID: 6584667
  39. Chemically induced hypotension increases PGE2 release and depresses macrophage antigen presentation.
    Am J Physiol. 1993 Apr;264(4 Pt 2):R655-60 PMID: 8476108
  40. Regulation of phospholipase A2 activation and arachidonic acid metabolism in an interleukin-3-dependent macrophage-like cell line.
    J Leukoc Biol. 1992 Jan;51(1):32-8 PMID: 1311011
  41. Differential effects of prostaglandins on macrophage activation induced by calcium ionophore A23187 or IFN-gamma.
    J Immunol. 1992 Feb 15;148(4):1171-5 PMID: 1310709
  42. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Cancer. 1993 Jul 15;72(2):491-501 PMID: 8319179
  43. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF.
    J Immunol. 1991 Jan 15;146(2):783-9 PMID: 1824777
  44. Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism.
    Cancer Res. 1993 Jul 15;53(14):3362-8 PMID: 8391924
  45. Selective homing of phenotypically lytic cells within nasopharyngeal carcinoma biopsies: numerous CD8- and CD16-positive cells in the tumor.
    Int J Cancer. 1991 Apr 22;48(1):57-61 PMID: 1826899
  46. Prostaglandin E2 receptor activity and susceptibility to natural killer cells.
    J Leukoc Biol. 1992 Feb;51(2):176-80 PMID: 1331278
  47. Interferon-gamma reduces tumor-induced Ia- macrophage-mediated suppression: role of prostaglandin E2, Ia, and tumor necrosis factor-alpha.
    Immunopharmacology. 1993 May-Jun;25(3):215-27 PMID: 8354638
  48. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.
    J Immunol. 1992 Dec 1;149(11):3495-502 PMID: 1358972
  49. Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage.
    Cancer Res. 1992 Jun 15;52(12):3425-31 PMID: 1596901
  50. Differential induction of prostaglandin E2-dependent and -independent immune suppressor cells by tumor-derived GM-CSF and M-CSF.
    J Leukoc Biol. 1993 Jan;53(1):86-92 PMID: 7678847
  51. Technique for the primary culture of human breast cancer cells and measurement of their prostaglandin secretion.
    Clin Sci (Lond). 1992 Sep;83(3):347-52 PMID: 1327654
  52. Local immunity and metastasis of colorectal carcinoma.
    Dis Colon Rectum. 1992 Jul;35(7):645-50 PMID: 1611952
  53. Ia- macrophages and cytokine networks contribute to tumor-induced suppression of CD4+ autoreactive T cells.
    Immunol Invest. 1993 Apr;22(3):169-87 PMID: 8099569
  54. LPS-induced activation of primed murine peritoneal macrophages is modulated by prostaglandins and cyclic nucleotides.
    Cell Immunol. 1993 Jun;149(1):50-64 PMID: 7685661
  55. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
    Cancer Res. 1991 Sep 1;51(17):4516-22 PMID: 1873795
  56. Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2.
    Lancet. 1992 Aug 15;340(8816):397-8 PMID: 1353559
  57. A new view of prostaglandin E regulation of the immune response.
    Immunol Today. 1991 Oct;12(10):349-52 PMID: 1958288
  58. Effect of prostaglandin E on immune function in normal healthy volunteers.
    Surg Gynecol Obstet. 1992 Oct;175(4):329-32 PMID: 1411890
  59. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels.
    J Immunol. 1992 May 1;148(9):2845-52 PMID: 1374102
  60. Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas.
    Eur J Immunol. 1990 Dec;20(12):2685-9 PMID: 1702723
  61. Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha.
    J Biol Chem. 1992 May 25;267(15):10816-22 PMID: 1587858
  62. Association of increased tumor cell responsiveness to prostaglandin E2 with more aggressive tumor behavior.
    Invasion Metastasis. 1991;11(1):48-57 PMID: 2061004
  63. Prostaglandin E2 does not inhibit tumoricidal activity of mouse macrophages against adherent tumor cells.
    J Immunol. 1991 Mar 15;146(6):2066-71 PMID: 2005391
  64. Changes in the populations of null, NK1.1+, and Thy1lo lymphocytes in the bone marrow of tumor-bearing mice: effect of indomethacin treatment.
    Cell Immunol. 1992 Jan;139(1):218-28 PMID: 1345896
  65. Effect of intravenous injection of IL-1 beta on PGE2 levels in several brain areas as determined by microdialysis.
    Am J Physiol. 1992 Feb;262(2 Pt 1):E246-51 PMID: 1539653
  66. Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells.
    Cancer Immunol Immunother. 1991;33(3):146-52 PMID: 1675153
  67. Tumor growth increases Ia- macrophage synthesis of tumor necrosis factor-alpha and prostaglandin E2: changes in macrophage suppressor activity.
    J Leukoc Biol. 1993 May;53(5):550-8 PMID: 8388910
  68. Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages.
    Biol Chem Hoppe Seyler. 1992 Sep;373(9):897-902 PMID: 1334672
  69. Molecular regulation of tumor necrosis factor-alpha and lymphotoxin production in T cells. Inhibition by prostaglandin E2.
    J Biol Chem. 1992 May 5;267(13):9443-9 PMID: 1533632
  70. Phorbol dibutyrate plus ionomycin improves the generation of cytotoxic T cells from draining lymph nodes of patients with advanced head and neck cancer.
    Am J Surg. 1992 Dec;164(6):610-4 PMID: 1463110
  71. A difference in prostaglandin-producing ability between cancer cells metastasized into liver and kidney.
    Tohoku J Exp Med. 1991 Dec;165(4):299-304 PMID: 1667958
  72. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.
    Cancer Res. 1992 Feb 15;52(4):775-81 PMID: 1737336
  73. Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.
    Cancer Immunol Immunother. 1994 Jan;38(1):9-15 PMID: 8299123
  74. Aspirin use and risk of fatal cancer.
    Cancer Res. 1993 Mar 15;53(6):1322-7 PMID: 8443812
  75. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis.
    Cancer Res. 1992 Nov 15;52(22):6335-40 PMID: 1423279
  76. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
    J Clin Oncol. 1993 Aug;11(8):1496-505 PMID: 8336188
  77. Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy.
    Int J Cancer. 1993 Jun 19;54(4):677-84 PMID: 8514459
  78. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
    J Natl Cancer Inst. 1992 May 6;84(9):694-9 PMID: 1569602
  79. Regulation of protein kinase A activation and prostaglandin E2-stimulated migration of Lewis lung carcinoma clones.
    Int J Cancer. 1991 Aug 19;49(1):150-5 PMID: 1651907
  80. Oligoclonal T lymphocytes infiltrating human lung cancer tissues.
    Int J Cancer. 1991 Mar 12;47(5):654-8 PMID: 1848534
  81. Immunomodulation in an apparently non-immunogenic murine tumor.
    Int J Cancer. 1991 Sep 30;49(3):414-20 PMID: 1833344
  82. Cytokine modulation of immune activation associated suppression of macrophage cyclooxygenase activity in vivo.
    Prostaglandins Leukot Essent Fatty Acids. 1992 Nov;47(3):231-8 PMID: 1475281
  83. IL-12 augments antigen-dependent proliferation of activated T lymphocytes.
    J Immunol. 1992 Dec 15;149(12):3778-83 PMID: 1360994
  84. Lipid-bound sialic acid, prostaglandin E and histamine in head and neck cancer.
    Eur J Cancer. 1993;29A(6):839-45 PMID: 8484973
  85. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma.
    Cancer. 1993 Apr 1;71(7):2326-31 PMID: 8453554
  86. Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.
    Cancer Immunol Immunother. 1992;35(2):119-26 PMID: 1534514
Article Info
Journal
Cancer metastasis reviews
Abbr.
Cancer Metastasis Rev
ISSN
0167-7659
DOI
10.1007/BF00666103
Published
1994-12-00
Pages
337-48
Language
English
Region
Netherlands
NLM ID
8605731
Subset
IM
Grants
NCI NIH HHS · CA-45080 · United States
NCI NIH HHS · CA-48080 · United States
External Links
PubMed source DOI: 10.1007/BF00666103 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2